|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
43,990,000 |
Market
Cap: |
656.33(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$12.17 - $24.61 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile REGENXBIO is a clinical-stage biotechnology company. Co.'s product candidates include: RGX-314, which is being developed as a gene therapy for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other additional chronic retinal conditions which cause total or partial vision loss for patients in the U.S., Europe and Japan; RGX-121, which is for the treatment of Mucopolysaccharidosis Type II; RGX-111, which is for the treatment of Mucopolysaccharidosis Type I; RGX-181, which is for the treatment of late infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease; and RGX-381, which is for the treatment of ocular manifestations of CLN2 disease.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
57,878 |
180,115 |
180,115 |
210,533 |
Total Sell Value |
$1,203,255 |
$3,323,210 |
$3,323,210 |
$4,306,417 |
Total People Sold |
2 |
2 |
2 |
3 |
Total Sell Transactions |
4 |
8 |
8 |
15 |
End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Hayden Donald J Jr |
|
|
2018-06-05 |
4 |
OE |
$0.85 |
$12,665 |
D/D |
14,900 |
14,900 |
|
- |
|
Hayden Donald J Jr |
|
|
2018-06-01 |
4 |
AS |
$55.00 |
$5,500 |
D/D |
(100) |
0 |
|
- |
|
Hayden Donald J Jr |
|
|
2018-06-01 |
4 |
OE |
$0.85 |
$85 |
D/D |
100 |
100 |
|
- |
|
Mills Kenneth T. |
President and CEO |
|
2018-05-21 |
4 |
AS |
$46.56 |
$470,540 |
D/D |
(10,000) |
208,530 |
|
- |
|
Hayden Donald J Jr |
|
|
2018-05-15 |
4 |
AS |
$50.06 |
$492,941 |
D/D |
(9,847) |
0 |
|
- |
|
Hayden Donald J Jr |
|
|
2018-05-15 |
4 |
OE |
$0.85 |
$8,370 |
D/D |
9,847 |
9,847 |
|
- |
|
Vasista Vittal |
Chief Financial Officer |
|
2018-05-15 |
4 |
AS |
$49.21 |
$375,721 |
D/D |
(7,500) |
144,783 |
|
- |
|
Hayden Donald J Jr |
|
|
2018-05-14 |
4 |
AS |
$50.04 |
$257,856 |
D/D |
(5,153) |
0 |
|
- |
|
Hayden Donald J Jr |
|
|
2018-05-14 |
4 |
OE |
$0.85 |
$4,380 |
D/D |
5,153 |
5,153 |
|
- |
|
Christmas Patrick J. |
SVP, General Counsel |
|
2018-05-10 |
4 |
OE |
$12.10 |
$181,500 |
D/D |
15,000 |
16,141 |
|
- |
|
Hayden Donald J Jr |
|
|
2018-05-09 |
4 |
AS |
$45.00 |
$675,000 |
D/D |
(15,000) |
0 |
|
- |
|
Hayden Donald J Jr |
|
|
2018-05-09 |
4 |
OE |
$0.85 |
$12,750 |
D/D |
15,000 |
15,000 |
|
- |
|
Christmas Patrick J. |
SVP, General Counsel |
|
2018-05-09 |
4 |
AS |
$42.00 |
$650,000 |
D/D |
(15,000) |
1,141 |
|
- |
|
Christmas Patrick J. |
SVP, General Counsel |
|
2018-05-09 |
4 |
OE |
$12.10 |
$181,500 |
D/D |
15,000 |
16,141 |
|
- |
|
Mills Kenneth T. |
President and CEO |
|
2018-04-20 |
4 |
AS |
$39.48 |
$395,205 |
D/D |
(10,000) |
218,530 |
|
- |
|
Vasista Vittal |
Chief Financial Officer |
|
2018-04-16 |
4 |
AS |
$37.34 |
$187,797 |
D/D |
(5,000) |
152,283 |
|
- |
|
Christmas Patrick J. |
SVP, General Counsel |
|
2018-04-11 |
4 |
AS |
$39.00 |
$390,000 |
D/D |
(10,000) |
1,141 |
|
- |
|
Christmas Patrick J. |
SVP, General Counsel |
|
2018-04-11 |
4 |
OE |
$12.10 |
$121,000 |
D/D |
10,000 |
11,141 |
|
- |
|
Christmas Patrick J. |
SVP, General Counsel |
|
2018-04-09 |
4 |
AS |
$34.00 |
$340,000 |
D/D |
(10,000) |
1,141 |
|
- |
|
Christmas Patrick J. |
SVP, General Counsel |
|
2018-04-09 |
4 |
OE |
$12.10 |
$121,000 |
D/D |
10,000 |
11,141 |
|
- |
|
Vasista Vittal |
Chief Financial Officer |
|
2018-03-26 |
4 |
AS |
$30.00 |
$150,000 |
D/D |
(5,000) |
157,283 |
|
- |
|
Mills Kenneth T. |
President and CEO |
|
2018-03-20 |
4 |
AS |
$29.55 |
$295,500 |
D/D |
(10,000) |
228,530 |
|
- |
|
Simpson Curran |
SVP, Technical Operations |
|
2018-03-13 |
4 |
S |
$33.00 |
$825,000 |
D/D |
(25,000) |
39,500 |
|
- |
|
Simpson Curran |
SVP, Technical Operations |
|
2018-03-13 |
4 |
OE |
$22.00 |
$550,000 |
D/D |
25,000 |
64,500 |
|
- |
|
Vasista Vittal |
Chief Financial Officer |
|
2018-03-06 |
4 |
OE |
$0.85 |
$51,000 |
D/D |
60,000 |
162,283 |
|
- |
|
404 Records found
|
|
Page 12 of 17 |
|
|